T3D 959

Drug Profile

T3D 959

Alternative Names: DB-959; DB-959Na; T3D-959

Latest Information Update: 16 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer DARA BioSciences; T3D Therapeutics
  • Class Antidementias; Antihyperglycaemics; Insulin sensitisers; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Alzheimer's disease
  • Discontinued Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Jul 2016 Interim efficacy and adverse events data from a phase IIa trial in Alzheimer's presented at the Alzheimer's Association International Conference 2016 (AAIC-2016)
  • 28 Jul 2016 T3D Therapeutics initiates a FDA-approved extension study in Alzheimer’s disease in USA before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top